McGill University researchers have supercharged natural killer cells to fight aggressive cancers by blocking two proteins that normally limit the immune cells’ tumor-killing activity, according to results published in May 2026.
Natural killer cells patrol the body for abnormal cells, but tumors often evade them through inhibitory signaling pathways. The team used genetic and pharmacological approaches to disable dual checkpoints, restoring robust cytotoxic responses in laboratory and animal models.
Investigators reported increased clearance of leukemia and solid tumor grafts without proportional growth in off-target toxicity compared with some prior cell therapy strategies. The approach may complement chimeric antigen receptor T-cell treatments by providing an alternative innate immune boost.
Clinical translation will require manufacturing protocols ensuring edited NK cells remain stable after infusion. McGill collaborators are discussing early-phase trial designs with hospital partners in Montreal’s cancer research network.
Immunotherapy advances continue reshaping oncology as pharmaceutical firms invest in combination regimens pairing checkpoint inhibitors with cell therapies. Independent reviewers praised mechanistic clarity but urged validation across diverse patient-derived tumor samples.
Funding agencies in Canada highlighted the work in national science announcements during spring budget releases.
Hospital partners in Montreal said early-phase planning will assess whether edited natural killer cells can be manufactured at scales required for multi-center oncology trials.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/